News

In each of the two placebo-controlled efficacy and safety trials, patients treated with tranexamic acid MR experienced a significant reduction in mean monthly menstrual blood loss compared with

According to Capricorn, korkoat beads accommodate high drug loads; modified drug release can be achieved by incorporating release-modifying agents inside the bead, in the coating, or in both.

This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery. IBI-20089 is a drug product based on Icon Bioscience’s

The PhotoMedex (PHMD) division provides mobile laser services in 11 Northeast, Mid-Atlantic and Southeast states, serving 18 individual local markets expanding PRI’s geographic coverage to a total of

Dr Gussak joins NewCardio from Boehringer Ingelheim Pharmaceuticals, where he held a senior executive role for the past year. Dr Gussak received his MD from Tartu University School

As part of the three-year agreement, the companies will employ the same underlying technology used in their previously announced joint project, a diagnostic for the differential diagnosis of

Sanofi-Aventis will pay Regeneron a minimum of $4.3 million annually for five years for knock-out and transgenic models of gene function for target genes identified by Sanofi-Aventis. Sanofi-Aventis

The purpose of the Phase I/II clinical trial is to evaluate the safety and tolerance of Triolex when administered orally for 28 days at three different dose levels.

Under the terms of the amended license agreement, XTL will receive an additional non-refundable payment of $2 million in return for reduction in future contingent payments. Under the